Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin

Pharmaceutical Research

Volumn 29, Issue 8, 2012, Pages 2104-2114

  Jonassen, Ib ^a   Havelund, Svend ^a   Hoeg Jensen, Thomas ^a   Steensgaard, Dorte Bjerre ^a   Wahlund, Per Olof ^a   Ribel, Ulla ^a  

^a NOVO NORDISK A S   (Denmark)

Author keywords

Acylated insulin; Basal insulin; Insulin analogue; Insulin degludec; Insulin hexamer

Indexed keywords

CARBROMAL; DIMER; FATTY ACID; HUMAN INSULIN; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN ZINC SUSPENSION; MONOMER; PHENOL; ZINC;

ACYLATION; ARTICLE; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG DESIGN; DRUG FORMULATION; DRUG STABILITY; DRUG STRUCTURE; GEL PERMEATION CHROMATOGRAPHY; LIGHT SCATTERING; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; ULTRAVIOLET RADIATION;

ACYLATION; AMINO ACID SEQUENCE; CHROMATOGRAPHY, GEL; CIRCULAR DICHROISM; FATTY ACIDS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; SERUM ALBUMIN;

EID: 84864460325     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0739-z     Document Type: Article

References (35)

1. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol. 2002;16(3):475-92.
2. Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DC, Mercola DA. Three-dimensional atomic structure of insulin and its relationship to activity. Diabetes. 1972;21(2 Suppl):492-505.
3. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L, Sorensen AR, Voigt HO. Monomeric insulins obtained by protein engineering and their medical implications. Nature. 1988;333:679-82.
4. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J, Kurtzhals P. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res. 2004;21:1498-504.
5. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53(6):1614-20.
6. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9(5):648-59.
7. DeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev. 2007;23(6):441-54.
8. Krüger P, Gilge G, Cabuk Y, Wollmer A. Cooperativity and intermediate states in the T R-structual transformation of insulin. Biol Chem Hoppe-Seyler. 1990;371:669-73.
9. Kaarsholm NC, Ko HC, Dunn MF. Comparison of solution structural flexibility and zinc binding domains for insulin, proinsulin, and miniproinsulin. Biochemistry. 1989;28(10):4427-35.
10. Jonassen I, Havelund S, Ribel U, Plum A, Loftager M, Hoeg-Jensen T, Volund A, Markussen J. Biochemical and physiological properties of a novel series of long-acting insulin analogs obtained by acylation with cholic acid derivatives. Pharm Res. 2006;23:49-55.
11. Jonassen I, Hoeg-Jensen T, Havelund S, Ribel-Madsen U, Tagmose TM, Madsen P. New insulin derivative comprising a naturally occurring insulin with a side chain attached to the alpha-amino or epsilonamino in the B chain of the parent insulin, useful in composition for treating diabetes. Patent registered by Novo Nordisk A/S and published in the Derwent World Patents Index (DWPI). Patent no. WO2005012347-A2.
12. Jorgensen KH. LarsenUD. Homogeneous mono-125I-insulins. Preparation and characterization of Mono-125I-(Tyr A14)- and Mono-125I-(Tyr A19)-insulin. Diabetologia. 1980;19:546-54.
13. Kruger P, Gilge G, Cabuk Y, Wollmer A. Cooperativity and intermediate states in the T;R-structural transformation of insulin. Biol Chem Hoppe Seyler. 1990;371:669-73.
14. Olsen HB, Kaarsholm NC. Structural effects of protein lipidation as revealed by Lys(B29)-myristoyl, des(B30) insulin. Biochemistry. 2000;39:11893-900.
15. Andrews P. Estimation of molecular size and molecular weights of biological compounds by gel filtration. Methods Biochem Anal. 1970;18:1-53.
16. Kurtzhals P, Ribel U. Action profile of cobalt(III)-insulin. A novel principle of protraction of potential use for basal insulin delivery. Diabetes. 1995;44(12):1381-5.
17. Perlmann GE, Longsworth LG. The specific refractive increment of some purified protein. J Am Chem Soc. 1948;70:2719-24.
18. Wen J, Arakawa T, Philo JS. Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions. Anal Biochem. 1996;240:155-66.
19. Theisen A, Johann C, Deacon MP, Harding SE. Refractive increment data-book. Nottingham: Nottingham University Press; 2000.
20. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J. Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. Biochem J. 1995;312:725-31.
21. Burchard W, Schmidt M, Stockmeyer WH. Information on polydispersity and branching from combined quasi-elastic and integrated scattering. Macromolecules. 1980;13:1265.
22. Choi WE, Brader ML, Aguilar V, Kaarsholm NC, Dunn MF. The allosteric transition of the insulin hexamer is modulated by homotropic and heterotropic interactions. Biochemistry. 1993;32 (43):11638-45.
23. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T. Albuminbound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9(3):290-9.
24. Heise T, Hövelmann U, Nosek L, Bøttcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold Longer Half-life and a more consistent pharmacokinetic profile than insulin glargine. Diabetes. 2011;60 Suppl 1:LB11.
25. den Engelsmann J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, JiskootW. Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res. 2011;28:920-33.
26. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself. 2010;1(4):314-22.
27. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J. 2006;8(3):E501-7.
28. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, LybyK, Jendle JH, Roberts AP, DeVries JH, Meneghini LF. Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011;34(3):661-5.
29. Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet. 2011;377(9769):924-31.
30. Heise T, Tack CJ, Cuddihy R, Davidson J, Gouet D, Liebl A, Romero E, Mersebach H, Dykiel P, Jorde R. A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naive people with type 2 diabetes: a randomized, controlled trial. Diabetes Care. 2011;34(3):669-74.
31. Kurtzhals P. How to achieve a predictable basal insulin? Diabetes Metab. 2005;31(4 Pt 2):4S25-33.
32. Heise T, Hermanski L, Nosek L, Feldmann A, Rasmussen S, Stryhn TK, Haahr H. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia. 2010;53(Suppl1):S387.
33. Kurzhals P, Heise T, Strauss HM, Bøttcher SG, Granhall C, Haahr H, Jonassen I. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Diabetes. 2011;60 Suppl 1:LB12.
34. Nosek L, Heise T, Bøttcher SG, Hastrup H, Haahr H. Ultra-longacting insulin degludec has a flat and stable glucose-lowering effect. Diabetes. 2011;60 Suppl 1:LB14.
35. Simon AC, Devries JH. The future of basal insulin supplementation. Diabetes Technol Ther. 2011;13 Suppl 1:S103-8.